一株人源性轮状病毒的分离及适应性培养

目的:研究轮状病毒野毒株的分离方法、组织培养适应条件及相应生物学性质.方法:对收集的样品采用胶体金、PCR、PAGE进行轮状病毒定性检测.阳性样品按常规方法处理并进行组织培养分离,对不同传代样品做基因组图谱、基因序列、病毒增殖动力学分析评价,采用轮状病毒P[8]G1型阳性血清进行病毒中和鉴别试验.结果:通过检测为A组轮状病毒,基因组为4∶2∶3∶2排列,基因分型G1P [8]型,在MA104细胞中传代后转至Vero细胞上适应培养可观察到CPE;电镜观察可见典型轮状病毒形态.毒株在Vero细胞上增殖到第10代,复制稳定,且感染性滴度达到7.25 log CCID50/ml,增殖高峰为96h.中和鉴别试验证实病毒培养液只包含轮状病毒,无其他病毒污染.结论:从腹泻样品中分离得到一株人源轮状病毒毒株,命名为ZTR-68株,该分离株具有良好的组织培养适应性,遗传稳定性,为进一步研究其生物学性质和疫苗制备提供了基础.     

细胞工厂在轮状病毒基因重配株LD9培养中的应用初探

为了探索用细胞工厂代替转瓶培养轮状病毒基因重配株LD9及收获高滴度的LD9病毒原液和提高产量的可行性,分别在2层4、层细胞工厂和3L1、5L转瓶培养Vero细胞,比较两种容器内细胞的生长状态。结果显示,以相同活细胞数2.5×104/ml同时接种两种不同培养容器时,细胞工厂培养3d已长成单层,而转瓶培养需5d;对两种容器长满单层时的细胞经胰酶消化后通过细胞仪计数、分析,结果显示,两种容器培养细胞长成单层时的单位面积细胞密度相当;对长成致密单层细胞的两种容器以相同的MOI(MOI=0.1)接种LD9病毒,转瓶培养的病毒于第8d病毒滴度达到高峰,为6.0～6.5 lgCCID50/ml;细胞工厂第5d病毒滴度达高峰,为6.5 lgCCID50/ml,并于第9d病毒滴度再次达到峰值,为6.0～6.5 lgCCID50/ml,实现二次收获病毒。     

Xfect介导重组质粒pEGFP-C2/LAT-ORF3高效转染Vero细胞的方法及其条件的优化

旨在用Xfect试剂介导重组质粒pEGFP-C2/LAT-ORF3转染Vero细胞,以期获得转染效率较高的方法,并检测目标片段的表达,从而为进一步研究HSV-2 LAT基因及其ORF3片段的生物学功能奠定基础。用Xfect试剂介导重组质粒pEGFP-C2/LAT-ORF3转染Vero细胞,48 h后观察荧光表达情况,并计算不同转染方法分别在有无血清及质粒与Xfect Polymer比例不同时的转染效率。用RT-PCR检测ORF3片段在Vero细胞中的表达。结果显示,采用贴壁转染法,在有血清及质粒与Xfect Polymer比例为5μg/2μL时转染效率较高;RT-PCR可以获得目的条带,证明ORF3片段在Vero细胞中得到表达。本试验获得的优化条件可以显著提高Xfect Polymer对Vero细胞的转染效率;以绿色荧光蛋白作为标签鉴定目的基因在细胞中表达的方法切实可行。     

重组HSV-Ⅱ病毒疫苗的微载体悬浮培养生产工艺研究

经过重组减毒的Ⅱ型溶瘤单纯疱疹病毒(rHSV-Ⅱ)在体外具有良好的溶瘤效果,并对小鼠体内B16R黑色素瘤内注射具有较高的疗效。重组HSV-Ⅱ病毒作为高效的新型溶瘤病毒疫苗有望用于肿瘤的临床治疗。Vero细胞是广泛应用于病毒疫苗生产的细胞基质,该细胞系对多种病毒敏感且产量高,其微载体培养安全,开发重组HSV-Ⅱ溶瘤病毒肿瘤疫苗的Vero细胞微载体反应器悬浮培养生产工艺具有重要的意义。以自主开发的低血清培养基为基础,对Vero细胞的反应器微载体球转球转移放大工艺及在位消化放大培养工艺进行了研究和比较,以新老微载体比3:1的比例成功实现了微载体球转球转移放大,建立了可实现至少四次/级连续放大的球转球转移放大培养工艺,可用于工业化生产过程。在此基础上,初步建立了以Vero细胞为基质的重组HSV-Ⅱ病毒疫苗反应器微载体无血清悬浮培养生产工艺,最大病毒滴度可达到6.62 lgTCID50/ml以上。为以Vero细胞为基质的无血清病毒疫苗规模化培养提供了一种简便、高效的工艺方法。     

Influence of the correlation modeling period on the prediction accuracy of infrared marker-based dynamic tumor tracking using a gimbaled X-ray head

PurposeTo assess the utility of 10 s and 20 s modeling periods, rather than the 40 s currently used, in the clinical construction of practical correlation models (CMs) in dynamic tumor tracking irradiation using the Vero4DRT.MethodsThe CMs with five independent parameters (CM parameters) were analyzed retrospectively for 10 consecutive lung cancer patients. CM remodeling was performed two or three times per treatment session. Three different CMs trained over modeling periods of 10, 20, and 40 s were built from a single, original CM log file. The predicted target positions were calculated from the CM parameters and the vertical displacement of infrared markers on the abdomen (P_IR) during the modeling. We assessed how the CM parameters obtained over modeling periods of T s (T = 10, 20, and 40 s) were robust to changes in respiratory patterns after several minutes. The mimic-predicted target positions after several minutes were computed based on the previous CM parameters and P_IR during the next modeling. The 95th percentiles of the differences between mimic-predicted and detected target positions over 40 s (E95_robust,T: T = 10, 20, and 40 s) were then calculated.ResultsStrong correlations greater than 0.92 were observed between the E95_robust,20 and E95_robust,40 values. Meanwhile, irregular respiratory patterns with inconsistent amplitudes of motion created differences between the E95_robust,10 and E95_robust,40 values of ≥10 mm.ConclusionsThe accuracies of CMs derived using 20 s were almost identical to those obtained over 40 s, and superior to those obtained over 10 s.     

In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line

The Middle East Respiratory Syndrome Coronavirus is well known to cause respiratory syndrome and this virus was identified and isolated for the first time from Jeddah, Saudi Arabia in 2012 from infected patient. In this report, we have conducted the in-silico prediction, designing and evaluation of siRNAs targeting Middle East Respiratory Syndrome Coronavirus orf1ab gene to inhibit the virus replication. By using bioinformatics software, total twenty-one functional, off-target reduced siRNA were selected from four hundred and sixty-two siRNAs based on their greater potency and specificity. We have evaluated only seven siRNAs to analyze their performance and efficacy as antivirals by reverse transfection approach in Vero cells. There was no cytotoxicity of siRNAs at various concentrations was observed in Vero cells. Based on the real-time PCR results, better inhibition of viral replication was observed in the siRNA-1 and 4 as compared to other siRNAs. The results generated from this work provided suitable information about the efficacy of siRNAs which encouraged us to further evaluate the remaining siRNAs to determine their inhibitory effect on the virus replication. We concluded that the insilico prediction and designing resulted in the screening of potential siRNAs with better efficiency, and strength. This can be used to develop oligonucleotide-based antiviral therapeutics against MERS-CoV in the near future.     

反刍动物产志贺毒素大肠杆菌的分离鉴定和致病潜力分析

产志贺毒素大肠杆菌（Shiga toxin-producing Escherichia coli,STEC）是重要的食源性病原,而STEC往往以正常菌群的形式存在于牛羊等反刍动物肠道。[目的] 本研究对牛羊粪便样品中的STEC分离和鉴定并对分离株进行致病潜力分析。从江苏、云南和河北等地共分离到羊源STEC菌株11株,牛源STEC菌株1株,另新疆农业大学佟盼盼组馈赠牛源菌株10株。[方法] 通过细菌选择培养及特异性基因stx1和stx2的检测进行分离鉴定;并通过Vero细胞毒性试验、溶血活性试验和毒力因子的检测分析STEC分离株的致病潜力。[结果] 分离到羊源分离株11株,分离率17.5%（11/63）;分离得到牛源分离株1株,分离率0.7%（1/134）;11株羊源分离株中有5株对Vero细胞具有强的毒性,3株有溶血活性;11株牛源分离株中有5株对Vero细胞具有强的毒性,3株有溶血活性。11株羊源STEC分离株eae基因携带率为63.6%（7/11）,而11株牛源STEC分离株eae基因携带率仅为9.0%（1/11）。[结论] 结果表明羊源STEC菌株的分离率和致病潜力高于牛源菌株,所以,除牛外,羊作为STEC菌株宿主也应该得到更多的重视。     

Ⅰ型单纯疱疹病毒感染的细胞培养系统的建立

目的:建立稳定的HSV-1感染的细胞培养系统,为HSV-1感染性皮肤病的基础及临床研究提供稳定的平台。方法:以猴肾细胞(Vero)为繁殖细胞,选择人鼻咽癌上皮细胞(Hep-2)为靶细胞,观察HSV-1在Hep-2株中的致细胞病变效应(CPE)。结果:HSV-1在Vero细胞中能稳定、大量地繁殖;HSV-1感染Hep-2细胞后可出现明显的细胞病变;结论:以Vero为繁殖细胞,Hep-2为靶细胞的稳定的细胞培养系统可作为HSV-1感染性皮肤病的基础及临床研究的平台。     

轮状病毒基因重配LH9株(G4型)传代稳定性研究

对兰州生物制品研究所自行构建的轮状病毒基因重配株G4型LH9株在Vero细胞中传代的稳定性进行研究。将基因重配LH9毒株接种于Vero细胞上从7代传至17代,经电镜检查、病毒滴度测定、病毒基因组RNA电泳图谱分析、基因序列测定分析、轮状病毒型别鉴定及其它相关检定,结果均符合药典要求。证实该毒株为A群G4P〔12〕型轮状病毒,在Vero细胞传代中具有良好的稳定性,为疫苗研制提供安全有效的依据。     

Standardization and validation of Vero cell assay for potency estimation of diphtheria antitoxin serum

Diphtheria toxin has the capacity to block protein synthesis in cultured mammalian cells, and thus causing cell death. This capacity of diphtheria toxin was utilized for in-vitro neutralization test to determine antibody titer, using Vero cells, which have been found to be susceptible to diphtheria toxin. In the present study, a Vero cell assay was standardized and validated for potency estimation of diphtheria antitoxin serum (DATS). The results obtained by Vero cell assay were compared with in-vivo biological assay. High degree of correlation (+0.98) was found between in-vivo biological assay and in-vitro Vero cell assay. The assay has also been found to be effective in determining the rising antibody titer in the equines inducted in DATS production. The present study indicated that although biological assays hold the key for final potency estimations till date but in the future scenario in-vitro Vero cell assay may be a good alternative to in-vivo biological assay.